Vernalis plc

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vernalis plc
Public company
Traded as LSEVER NASDAQVNLS
Industry Biotechnology
Founded 2003
Headquarters Winnersh, United Kingdom
Key people
Ian Garland
(CEO)
Peter Fellner
(Executive chairman)
Products Frovatriptan, Apokyn
Number of employees
200
Website vernalis.com

Vernalis plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.[1] The merger allowed British Biotech to ditch its historic but tarnished name.[2]

The company has marketed two drug products; Frovatriptan,[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.[4]

The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono. It is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.

References[edit]

  1. ^ "Vernalis agrees £91m merger plan with British Biotech". Advances in Life Science. ALS. 2003. Retrieved 3 July 2003. 
  2. ^ "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 28 November 2007. 
  3. ^ "Patient Information Sheet – Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 29 September 2007. Retrieved 28 November 2007. 
  4. ^ "Apokyn". FDA. 2004. Retrieved 29 July 2004. [dead link]

External links[edit]